QR678® Neo is a breakthrough, patented non-surgical hair restoration treatment developed by globally recognised Indian surgeons Dr. Debraj Shome and Dr. Rinky Kapoor. It consists of a proprietary, plant-derived biomimetic growth factor formulation — containing precisely engineered peptides that mimic the body’s natural hair growth signals — which is injected intradermally into the scalp to directly reactivate dormant hair follicles and trigger robust, healthy hair regrowth.
Unlike PRP (Platelet-Rich Plasma) which requires blood extraction and centrifugation with variable outcomes, QR678® Neo is a ready-to-use, standardised, pharmaceutical-grade formulation — meaning every session delivers an identical, precisely calibrated concentration of growth factors. This standardisation is one of the key reasons QR678® consistently outperforms PRP in head-to-head clinical studies published in peer-reviewed journals.

Each QR678® peptide is engineered with a signal sequence — a short amino acid chain designed to bind to specific receptors on hair follicle cell membranes. Once bound, they send precise regenerative instructions exactly where needed, without affecting surrounding tissue.

Growth factors VEGF, KGF, FGF, and IGF directly target miniaturised and dormant hair follicles — reactivating their growth cycle, extending the anagen (active growth) phase, and reversing the follicle miniaturisation caused by DHT in androgenetic alopecia.

The formulation protects follicles from the damaging effects of Dihydrotestosterone (DHT) — the hormone responsible for male and female pattern hair loss — shielding follicle receptors from progressive miniaturisation and shedding.

VEGF (Vascular Endothelial Growth Factor) stimulates the formation of new blood vessels around follicles — dramatically improving the supply of oxygen and essential nutrients directly to the hair roots for sustained growth.

QR678® activates resident hair follicle stem cells in the bulge region — the regenerative reservoir of each follicle — triggering them to proliferate and generate new, healthy hair strands with greater shaft diameter and density.

Growth factors also stimulate dermal fibroblasts to produce new collagen in the scalp — improving the structural environment surrounding each follicle, strengthening roots, and creating an optimal foundation for long-term hair health.

Male pattern baldness (receding hairline, crown thinning). The strongest clinical data — 100% reduction in hair fall at 6 months in published studies. Most effective for Norwood grades II–IV.

Diffuse thinning over the crown and parting in women. Published case studies show significant regrowth including in post-menopausal patients who failed PRP and other treatments.

Stress-induced, post-illness, or post-Covid hair shedding. A published PubMed study (2021) specifically validated QR678® Neo for Covid-19-induced persistent telogen effluvium with strong results.

A published PubMed study (2020) demonstrated QR678® is safe and significantly effective for chemotherapy-induced hair loss — with improvement maintained at 1-year follow-up. A unique and important clinical application.

Given 3–4 weeks post hair transplant to accelerate graft healing, improve graft survival rates, and stimulate growth in existing native hairs. Also used pre-transplant to reduce the area requiring transplantation.

Localised circular patches of hair loss from autoimmune causes. QR678® can support regrowth in the affected areas — used alongside other therapies as part of a comprehensive alopecia areata management protocol.

Your dermatologist performs a thorough scalp examination — assessing hair loss pattern (Norwood scale for men, Ludwig scale for women), hair pull test, trichoscopy / videomicroscopy to evaluate vellus vs terminal hair ratio, scalp health, and underlying causes. Blood tests may be recommended to rule out nutritional deficiencies or thyroid/hormonal causes.

The scalp is thoroughly cleansed to remove any styling products, oils, or debris. The treatment area is mapped and divided into injection zones for systematic and complete coverage of all thinning and affected areas.

A topical anaesthetic cream may be applied for 20 minutes before the procedure for sensitive patients, though most patients tolerate QR678® injections with minimal discomfort. The needles used are ultra-fine insulin-gauge needles that cause minimal pain.

The pre-prepared, ready-to-use QR678® Neo solution is loaded into a fine-gauge syringe. Using a series of precise intradermal microinjections (or a mesotherapy gun / microneedling device), 1.5–2 mL of the formulation is delivered systematically across the entire scalp treatment area — targeting the dermal layer at approximately 2–4 mm depth for optimal follicle contact. The procedure takes 10–20 minutes.

A gentle scalp massage is performed after the injections to evenly distribute the QR678® solution across the scalp and stimulate local blood circulation — enhancing the uptake and distribution of growth factors into the follicular tissue.

A complete session schedule is discussed — typically 8–12 sessions spaced every 2–4 weeks for the initial course, followed by maintenance sessions. A supportive homecare regimen (specific shampoos, minoxidil if appropriate, nutritional supplements) is prescribed to maximise and sustain treatment results.